Aduro Biotech, Inc. (NASDAQ:ADRO) insider Thomas W. Dubensky sold 40,912 shares of the business’s stock in a transaction dated Thursday, August 10th. The stock was sold at an average price of $11.43, for a total transaction of $467,624.16. Following the completion of the sale, the insider now owns 80,812 shares in the company, valued at $923,681.16. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Aduro Biotech, Inc. (NASDAQ ADRO) traded up 1.79% on Friday, reaching $11.35. 379,430 shares of the company’s stock were exchanged. The firm’s 50 day moving average is $12.44 and its 200 day moving average is $10.98. The stock’s market capitalization is $846.85 million. Aduro Biotech, Inc. has a 1-year low of $8.75 and a 1-year high of $16.15.

Aduro Biotech (NASDAQ:ADRO) last released its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.27) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.25) by $0.02. Aduro Biotech had a negative net margin of 609.58% and a negative return on equity of 43.92%. The company had revenue of $5.90 million during the quarter, compared to analyst estimates of $3.98 million. During the same quarter last year, the business earned $0.03 EPS. The company’s revenue for the quarter was down 84.9% compared to the same quarter last year. Analysts expect that Aduro Biotech, Inc. will post ($1.37) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This piece was first published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/08/11/aduro-biotech-inc-nasdaqadro-insider-thomas-w-dubensky-sells-40912-shares.html.

Several institutional investors have recently added to or reduced their stakes in the stock. Parametric Portfolio Associates LLC raised its position in Aduro Biotech by 82.6% in the second quarter. Parametric Portfolio Associates LLC now owns 28,160 shares of the biotechnology company’s stock worth $321,000 after buying an additional 12,736 shares during the period. Vanguard Group Inc. raised its position in Aduro Biotech by 5.4% in the second quarter. Vanguard Group Inc. now owns 2,511,995 shares of the biotechnology company’s stock worth $28,637,000 after buying an additional 129,079 shares during the period. Northern Trust Corp raised its position in Aduro Biotech by 15.1% in the second quarter. Northern Trust Corp now owns 453,115 shares of the biotechnology company’s stock worth $5,166,000 after buying an additional 59,490 shares during the period. New York State Common Retirement Fund raised its position in Aduro Biotech by 21.3% in the second quarter. New York State Common Retirement Fund now owns 51,200 shares of the biotechnology company’s stock worth $584,000 after buying an additional 8,999 shares during the period. Finally, Nationwide Fund Advisors raised its position in Aduro Biotech by 12.5% in the second quarter. Nationwide Fund Advisors now owns 23,112 shares of the biotechnology company’s stock worth $263,000 after buying an additional 2,567 shares during the period. Institutional investors and hedge funds own 35.60% of the company’s stock.

Several equities research analysts recently commented on the stock. BidaskClub lowered shares of Aduro Biotech from a “hold” rating to a “sell” rating in a research report on Tuesday. Canaccord Genuity set a $30.00 price objective on shares of Aduro Biotech and gave the stock a “buy” rating in a research report on Thursday, August 3rd. HC Wainwright set a $18.00 price objective on shares of Aduro Biotech and gave the stock a “buy” rating in a research report on Thursday, August 3rd. Zacks Investment Research lowered shares of Aduro Biotech from a “buy” rating to a “hold” rating in a research report on Wednesday, August 2nd. Finally, Cowen and Company assumed coverage on shares of Aduro Biotech in a research report on Tuesday, July 18th. They issued an “outperform” rating on the stock. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the company. Aduro Biotech currently has a consensus rating of “Buy” and a consensus price target of $19.00.

Aduro Biotech Company Profile

Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.

Insider Buying and Selling by Quarter for Aduro Biotech (NASDAQ:ADRO)

Receive News & Ratings for Aduro Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro Biotech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.